Search GO Type Size: Smaller Normal Larger Print This Page


Important Safety Information
Full Prescribing Information




This information is intended for US healthcare professionals

Proven Efficacy

Prompt Improvement in Serum Sodium Concentration

Double-blind serum sodium graph

Study design: Results from a double-blind, placebo-controlled, randomized, multicenter study in patients with euvolemic or hypervolemic hyponatremia (serum sodium 115-130 mEq/L). Fluid restricted to ≤2.0 L/day in all patients. The mean baseline serum sodium concentration in patients treated with Vaprisol was 123.3 mEq/L vs 124.3 mEq/L for placebo.

  • A 6.5 mEq/L mean change from baseline in serum sodium concentration was achieved at the end of Vaprisol treatment (96 hours) compared with 1.5 mEq/L with placebo1
  • 69% of patients achieved a ≥6 mEq/L increase in serum sodium concentration or normal serum sodium by day 4 (end of treatment) with Vaprisol compared with 21% of patients with placebo1
    • By day 2, 41% achieved a ≥6 mEq/L increase in serum sodium concentration or normal serum sodium compared with 0% of patients with placebo1

There has been no demonstrated osmotic demyelination in trials with Vaprisol.1


Reference: 1. Vaprisol Prescribing Information. Astellas Pharma US, Inc.

Stay Informed

Register to receive additional information and important updates about Vaprisol.

Click here

Vaprisol Works Differently—Find Out How

Learn more about how first-in-class Vaprisol targets AVP to lower serum [Na+].

Click Here

Using Vaprisol in Your Patients

Learn how to use Vaprisol in a wide range of patients with dilutional hyponatremia.

Click here